Skip to main content

bedaquiline (Sirturo®)

 

Status: In progress

For use as part of an appropriate combination regimen for pulmonary multidrug‑resistant tuberculosis (MDR‑TB) in paediatric patients (5 years to less than 12 years of age and weighing at least 15 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Medicine details

Medicine name bedaquiline (Sirturo®)
Formulation 100 mg tablet, 20 mg tablet
Reference number 4860
Indication

As above

Company Janssen-Cilag Ltd
BNF chapter Infections
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date TBC
Date of issue TBC
Further information

AWMSG advice for use of bedaquiline in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) 

Follow AWTTC: